Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment.

PURPOSE To evaluate previously determined predictors of metastasis in low-stage testis cancer in a consecutive group of clinical stage A patients. PATIENTS AND METHODS Ninety-one consecutive clinical stage A nonseminomatous germ cell tumor (NSGCT) patients who underwent primary nerve-sparing retroperitoneal lymph node dissection (NSRPLND) had orchiectomy specimens and computed tomographic (CT) scans evaluated blindly in a quantitative fashion. These scores were then correlated with pathologic stage using previously determined paradigms. RESULTS Using volume of embryonal carcinoma in the orchiectomy specimen, lymph node diameters in the primary landing zones and MIB-1 staining of the orchiectomy specimen, 41 patients were classified as low risk for metastasis. Forty of these 41 had pathologic stage A disease at RPLND. CONCLUSION These parameters can identify a low-risk group of patients for metastasis who can be rationally offered surveillance.

[1]  K. Kopecky,et al.  Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. , 1995, The Journal of urology.

[2]  T. Ulbright,et al.  Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis , 1995, Cancer.

[3]  P. Albers,et al.  Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors , 1994, Cancer.

[4]  J. Donohue,et al.  Complications of primary retroperitoneal lymph node dissection. , 1994, The Journal of urology.

[5]  J. Moul,et al.  Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. , 1994, Cancer research.

[6]  J. Donohue,et al.  Retroperitoneal lymphadenectomy for clinical stage a testis cancer: Modifications of technique and impact on ejaculation , 1994 .

[7]  J. Moul,et al.  Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. , 1993, The Journal of urology.

[8]  J. Thornhill,et al.  Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. , 1993, The Journal of urology.

[9]  J. Donohue Unsolved problems in testis cancer. , 1993, European urology.

[10]  A. Horwich,et al.  Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Donohue,et al.  Complications of retroperitoneal lymph node dissection. , 1981, The Journal of urology.